Science and Research

[Integration of Inventory Data from Cohort and Registry Studies into an Existing Research Network: National Pandemic Cohort Network (NAPKON)]

In the early phase of the COVID-19 pandemic, many local collections of clinical data on patients infected with SARS-CoV-2 were initiated in Germany. As part of the National Pandemic Cohort Network (NAPKON) of the University Medicine Network, the "Integration Core" was established to design the legal, technical and organisational requirements for the integration of inventory data into ongoing prospective data collections and to test the feasibility of the newly developed solutions using use cases (UCs). Detailed study documents of the data collections were obtained. After structured document analysis, a review board evaluated the integrability of the data in NAPKON according to defined criteria. Of 30 university hospitals contacted, 20 responded to the request. Patient information and consent showed a heterogeneous picture with regard to the pseudonymised transfer of data to third parties and re-contact. The majority of the data collections (n=13) met the criteria for integration into NAPKON; four studies would require adjustments to the regulatory documents. Three cohorts were not suitable for inclusion in NAPKON. The legal framework for retrospective data integration and consent-free data use via research clauses (§27 BDSG) was elaborated by a legal opinion by TMF - Technology, Methods and Infrastructure for Networked Medical Research, Berlin. Two UCs selected by the NAPKON steering committee (CORKUM, LMU Munich; Pa-COVID-19, Charité- Universitätsmedizin Berlin) were used to demonstrate the feasibility of data integration in NAPKON by the end of 2021. Quality assurance and performance-based reimbursement of the cases were carried out according to the specifications. Based on the results, recommendations can be formulated for various contexts in order to create technical-operational prerequisites such as interoperability, interfaces and data models for data integration and to fulfil regulatory requirements on ethics, data protection, medical confidentiality and data access when integrating existing cohort data. The possible integration of data into research networks and their secondary use should be taken into account as early as the planning phase of a study - particularly with regard to informed consent - in order to maximise the benefits of the data collected.

  • Hofmann, A. L.
  • Vehreschild, J. J.
  • Witzenrath, M.
  • Hoffmann, W.
  • Illig, T.
  • Schreiber, S.
  • Anton, G.
  • Hellmuth, J. C.
  • Muenchhoff, M.
  • Scherer, C.
  • Pley, C.
  • Thibeault, C.
  • Kurth, F.
  • Berger, S.
  • Hummel, M.
  • Hopff, S. M.
  • Stecher, M.
  • Appel, K.
  • Stahl, D.
  • Kraus, M.
  • Lorenz-Depiereux, B.
  • Hanß, S.
  • von Kielmansegg, S.
  • Schlünder, I.
  • Niemeyer, A.
  • Heuschmann, P.
  • Krawczak, M.
  • Reese, J. P.
Publication details
DOI: 10.1055/a-2346-9680
Journal: Gesundheitswesen
Work Type: Original
Location: Assoziierter Partner
Disease Area: PALI
Partner / Member: BIH
Access-Number: 39173676

DZL Engagements

chevron-down